Xlumena’s portfolio includes the AXIOS and HOT AXIOS Stent and Delivery Systems. The AXIOS system has FDA clearance and a CE Mark. The next-generation HOT AXIOIS system has a CE Mark.
Boston Scientific will pay $62.5 million upfront and an additional $12.5 million when the HOT AXIOS system receives FDA clearance.
“We believe the acquisition of Xlumena and their minimally-invasive products combined with the Boston Scientific broad product portfolio demonstrates our commitment to advancing the field of interventional EUS therapeutics,” said David Pierce, senior vice president and president of endoscopy at Boston Scientific.
More articles on gastroenterology:
Dr. Kevin Byrne honored by Lake Regional Health System
Case study: Upright reflux treatment with Stretta
Number of ED visits for constipation on the rise
